Business
Nutriband's Innovative Patent Breaks New Ground in Transdermal Medications
Orlando, FL, Sept 20, 2023 - (ACN Newswire) - - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products,
About this update from Nutriband Inc.
[{"type":"text","content":"Orlando, FL, Sept 20, 2023 - (ACN Newswire) - - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches.The newly granted patent, numbered U.S. patent 11,759,431, titled \"Abuse and Misuse Deterrent Transdermal Systems,\" significantly bolsters Nutriband's intellectual property protection in the United States. It covers a range of abuse deterrent transdermal products, all rooted in the proprietary AVERSA abuse deterrent technology. This pioneering technology seamlessly integrates into transdermal patches, effectively countering abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's flagship product in development, AVERSA Fentanyl, leads the charge in revolutionizing pain management. It aims to become the market's premier abuse deterrent pain patch, setting new standards for safety. This patent signifies a pivotal milestone in Nutriband's strategic vision to fortify its intellectual property foundation around its proprietary abuse deterrent technology. With a global reach encompassing 45 countries, Nutriband's IP portfolio solidifies its position in the market. AVERSA Fentanyl, the company's flagship product, recently projected peak annual U.S. sales ranging from $80M to $200M.Nutriband's AVERSA abuse deterrent transdermal technology presents a transformative solution to enhance the safety profile of transdermal drugs susceptible to abuse. AVERSA not only ensures continued access for patients in need but also minimizes the risk of abuse, diversion, misuse, and accidental exposure. Backing this pioneering technology is a robust intellectual property portfolio, with patents granted in various countries, including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia. About Nutriband Inc.Nutriband Inc. is a leader in developing transdermal pharmaceutical products. At the forefront is the company's flagship product, an abuse deterrent fentanyl patch incorporating the groundbreaking AVERSA abuse-deterrent technology. AVERSA technology can be seamlessly integrated into a...